Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: a case report.

Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as linagliptin, have been implicated in inducing bullous pemphigoid (BP) in elderly diabetic patients. Stapokibart is a humanized monoclonal antibody targeting interleukin-4 receptor subunit alpha (IL-4Rα), primarily used for atopic dermatitis, with no prior reports of its application in BP. This article describes a case of DPP-4 inhibitor-induced bullous pemphigoid treated with Stapokibart. Following Stapokibart therapy, the patient exhibited complete resolution of skin lesions, significant improvement in quality of life, and no adverse reactions. This case suggests that Stapokibart may be an effective treatment for bullous pemphigoid induced by DPP-4 inhibitors.